Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$130.97 USD

130.97
2,220,050

+0.76 (0.58%)

Updated Sep 18, 2024 04:00 PM ET

After-Market: $131.00 +0.03 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Zoetis Stock Rises 15% in 3 Months: Time to Add to Your Portfolio?

ZTS' innovative pet care products, along with efforts to expand the business, are expected to fuel significant growth in the future.

RCKT Completes Enrollment in Rare Heart Disease Study, Stock Rises

Rocket completes enrollment of patients in a pivotal phase II study evaluating RP-A501 for treating male patients with Danon disease.

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

Ascendis Soars on Encouraging Data From Dwarfism Drug Study

ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.

NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.

Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies

ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.

Here's Why Investors Should Invest in Arcturus Stock Now

Here, we are discussing some reasons why investing in ARCT stock now may turn out to be a prudent move.

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study

Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study.

FULC Stock Falls as Muscle Disorder Study Misses Primary Goal

The phase III REACH study evaluating Fulcrum's losmapimod for treating facioscapulohumeral muscular dystrophy fails to meet the primary endpoint.

Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study

AURA stock up as lead candidate shows tumor control and visual acuity preservation abilities in eye cancer patients over 12 months of treatment.

Should SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) Be on Your Investing Radar?

Style Box ETF report for SPMD

FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer

The FDA bestows an orphan drug designation to Agios' PK activator, tebapivat, for treating myelodysplastic syndromes.

ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down

Iterum provides updates from the FDA's Antimicrobial Drugs Advisory Committee meeting on its NDA for oral sulopenem to treat adult women with uUTI.

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study

The FDA removes the partial clinical holds on Rezolute's phase III study evaluating RZ358 for treating congenital hyperinsulinism.

Illumina and Exxon Mobile have been highlighted as Zacks Bull and Bear of the Day

Illumina and Exxon Mobile have been highlighted as Zacks Bull and Bear of the Day.

David Bartosiak headshot

Bull of the Day: Illumina (ILMN)

Big jump after earnings led by a pullback, could be an opportunity here.

Rocket Stock Down More Than 30% in Past Six Months: Here's Why

The recent regulatory setbacks related to RCKT's pipeline candidate, Kresladi (marnetegragene autotemcel) weigh heavily on the stock.

IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab

Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy options.

Should Vanguard S&P Mid-Cap 400 Value ETF (IVOV) Be on Your Investing Radar?

Style Box ETF report for IVOV

Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient

HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin toxicities.

Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals

BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.

ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal

Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

Affimed Appoints New CEO, Shares Fall on Leadership Change

AFMD appoints Shawn M. Leland as the company's new chief executive officer. Stock falls on the news.

Recursion Stock Down Despite Meeting Goal in Brain Disease Study

RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.